Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17275134 | 1.00 | MAPK1 (0.44) | MAPK1KDM4EHIF1APRMT1ALDH1A1 | |
| SCHEMBL20919713 | 1.00 | MAPK1 (0.44) | MAPK1KDM4EHIF1APRMT1ALDH1A1 | |
| SCHEMBL15194211 | 1.00 | MAPK1 (0.44) | MAPK1KDM4EHIF1APRMT1ALDH1A1 | |
| SCHEMBL4230147 | 1.00 | MAPK1 (0.44) | MAPK1KDM4EHIF1APRMT1ALDH1A1 | |
| SCHEMBL3050112 | 1.00 | MAPK1 (0.44) | MAPK1KDM4EHIF1APRMT1ALDH1A1 | |
| SCHEMBL4155026 | 1.00 | MAPK1 (0.44) | MAPK1KDM4EHIF1APRMT1ALDH1A1 | |
| SCHEMBL17634017 | 1.00 | MAPK1 (0.44) | MAPK1KDM4EHIF1APRMT1ALDH1A1 | |
| SCHEMBL3051327 | 0.97 | — | — | |
| SCHEMBL379211 | 0.90 | — | — | |
| SCHEMBL20836564 | 0.87 | KDM4E (0.55) | MAPK1KDM4EHIF1APRMT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11739101-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023143482-A1 | 2-AMINOPYRIMIDINE COMPOUND OR SALT, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海辉启生物医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4168003-A2 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230096517-A1 | GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-03-30 | — | — | US | disclosed |
| EP-4146660-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4112614-A1 | GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF | Shanghaitech University (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
| US-20210355140-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | GILEAD SCIENCES, INC. | 2021-11-18 | — | — | US | disclosed |
| WO-2021226262-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3778590-A1 | PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE | ShanghaiTech University (CN) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020219650-A1 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| EP-1999107-A2 | AMINE DERIVATIVES | Pfizer Limited (GB) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107828-A2 | AMINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| EP-1691807-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | Astellas Pharma Inc. (JP) | 2006-08-23 | — | — | EP | disclosed |
| US-20050245540-A1 | New methods | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| WO-2005056012-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | ASTELLAS PHARMA INC. (JP) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | MAPK1 2223/4885KDM4E 2034/4885HIF1A 3866/4885 |
| US-11739101-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | TTK, HIPK1, HIPK2 | MAPK1 1494/4885KDM4E 1247/4885HIF1A 1111/4885 |
| US-20230096517-A1 | GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF | GLS, GCDH, GLS2 | MAPK1 2290/4885KDM4E 2458/4885HIF1A 2151/4885 |
| US-20210355140-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, HIPK2 | MAPK1 1494/4885KDM4E 1247/4885HIF1A 1111/4885 |
| US-20050245540-A1 | New methods | TGFB1, TGFBR1, TGFB2 | MAPK1 825/4885KDM4E 3172/4885HIF1A 68/4885 |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | MAPK1 394/4885KDM4E 4494/4885HIF1A 1251/4885 |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, HIPK2 | MAPK1 1494/4885KDM4E 1247/4885HIF1A 1111/4885 |
| US-20090253739-A1 | Amine Derivatives | HNMT, HRH4, CMA1 | MAPK1 1127/4885KDM4E 1691/4885HIF1A 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.